Replies to post #263687 on Avid Bioservices Inc (CDMO)

[itsabouttime]

Food for thought feeds the appetite.

[Protector]

tradero, almost nobody commented probably because while bavituximab would fit the shoe there is no way to tell that it is Bavituximab.

There are many I-O drugs and many in cancer. How many of those are also in Viral, I don't know. Bavituximab is.

But until there, many could qualify I figure. But if you add SAFETY without damaging cells (as the researcher says) then there will be not many left except Bavituximab and very few others as we know all those I-O drugs have tremendous side effects.

But that is not the basis on which you should have found this article interesting IMO. What is MUCH MORE pointing in the direction of Bavituximab is the ROLE of caspase 3. It is actually part of the apoptosis cycle (natural cell death) and phosphatidylserine is the ABSOLUTE #1 orchestra leader of that cycle. It binds at least 7 receptors that we know on cells during that cycle. Caspase-3 (a cysteine peptidase) is found in the apoptic cells, those cells where PS is exposed.
Caspase, when activated by apoptic signalling, actually destroys cell without discrimination and therefore must be regulated. Actually the best soldier for an hostile virus to activate.

So if I believe there could be a chance that the drug the Doctor at John Hopkins talked about could be Bavituximab then it would be based on that because IMO it is the most 'filtering' element leaving very few, if any, other drug candidates.

And remember it is a drug that is not approved yet, so we can exclude the PD-1/PD-L1 and CTLA-4 drugs because they all have been approved in some larger or smaller cancer condition.